IpilimumabNivolumab - Share Your Cancer Stories | Cancer News & Awareness Updates

Browsing: IpilimumabNivolumab

Diagnosis

Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population

By NewsCancerMarch 5, 20260

According to Antonio Ocejo, MD, patients with renal cell carcinoma (RCC) 70 years and older may derive similar overall survival…

Survivors

Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC

By NewsCancerFebruary 28, 20260

The addition of stereotactic body radiation therapy (SBRT) to ipilimumab (Yervoy) and nivolumab (Opdivo) did not confer improved progression-free survival…

What's Hot

A design approach for bitopic kinase inhibitors

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma

Browsing: IpilimumabNivolumab

Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population

Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC

A design approach for bitopic kinase inhibitors

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

A design approach for bitopic kinase inhibitors

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Latest Post

A design approach for bitopic kinase inhibitors

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: IpilimumabNivolumab